Eli Lilly to Acquire SiteOne Therapeutics for Up to USD 1 Billion
US-based pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) announced plans to acquire compatriot biotech...
Biotech
BeiGene Rebrands to BeOne Medicines and Relocates to Switzerland
BeiGene (NASDAQ: ONC, HKG: 6160, SHA: 688235), a global oncology company, has officially rebranded to...
Sichuan Kelun-Biotech Finalizes Licensing Deal for TSLP Monoclonal Antibody
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) announced that it has received the upfront...
Shandong Boan Biotechnology Partners with HKUST for Biomedicine Innovation
China-based Shandong Boan Biotechnology Co., Ltd (HKG: 6955) has entered into a partnership with the...
Guangzhou Regenverse Therapeutics Raises RMB 100 Million in Pre-Series A Financing
China-based Guangzhou Regenverse Therapeutics Co., Ltd (former name: Guangzhou Regen Therapeutics Co., Ltd.), a developer...
LTZ Therapeutics Secures $40M Series A+ to Advance Immunotherapy Pipeline
Shenzhen-based LTZ Therapeutics has reportedly raised USD 40 million in a Series A+ financing round...
Merck KGaA Nears Completion of $3.5 Billion Acquisition of SpringWorks Therapeutics
German pharmaceutical major Merck KGaA (ETR: MRK) is reportedly nearing the completion of its acquisition of...
Shineco Inc. Announces Acquisition of InfiniClone for Regenerative Medicine Expansion
US-based Shineco Inc. (NASDAQ: SISI) announced that its subsidiary Shineco Life Sciences Group Hong Kong...
Boehringer Ingelheim Partners with Tessellate Bio on ALT Cancer Therapies
Boehringer Ingelheim (BI), a German pharmaceutical leader, has entered into a strategic collaboration and global...
Johnson & Johnson Reports Q1 2025 Revenue Growth, Led by Innovative Medicines and MedTech
US pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) reported Q1 2025 revenues of USD...
RemeGen’s 2024 Revenue Soars 58.54% on Strong Product Sales and R&D Growth
China-based biotech RemeGen Co., Ltd (HKG: 9995, SHA: 688331) released its 2024 financial report, recording...
Alphamab Oncology Reports 192.58% Revenue Surge Led by Envafolimab
Alphamab Oncology (HKG: 9966) has announced its 2024 financial results, marking a significant milestone with...
Everest Medicines Reports Surge in Revenue, Advances Core Products and R&D Pipeline
China-based Everest Medicines (HKG: 1952) has announced its 2024 financial results, marking a significant milestone...
Sichuan Kelun-Biotech Reports 25.5% Revenue Growth with Key Drug Approvals
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has released its 2024 financial report, recording...
Eli Lilly Launches Lilly Gateway Laboratory in China to Boost Biotech Innovation
US major Eli Lilly & Co., (NYSE: LLY) has announced the opening of the Lilly...
Syneron Bio Collaborates with AstraZeneca to Develop Macrocyclic Peptides for Chronic Diseases
China-based Syneron Bio, a biotech firm specializing in macrocyclic peptide drugs, has entered into a...
Harbour BioMed Partners with AstraZeneca on Multi-Specific Antibody Development
China-based Harbour BioMed (HKG: 2142) has formed a strategic partnership with UK pharmaceutical giant AstraZeneca...
Kexing Biopharm and Hinova Forge Alliance to Expand Global Market Reach
China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced this week a strategic alliance with compatriot...
Paratek Pharmaceuticals to Acquire Optinose for $330 Million
Paratek Pharmaceuticals and Optinose, Inc. (NASDAQ: OPTN) announced a definitive merger agreement on March 19,...
Harbour BioMed Appoints Michael D. Patten as Chief Strategy Officer to Lead Global Growth
China-based Harbour BioMed (HKG: 2142) announced the appointment of Michael D. Patten as Chief Strategy...